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hyroid cancer is the most common endocrine
malignancy in the United States, but ana-
plastic thyroid cancer (ATC) constitutes only
1% of these cases.1 This histology confers a partic-
ularly poor prognosis with a median survival of only
3–5 months.2 Patients usually succumb to local
invasion, as ATC metastasizes in only 10%–20% of
cases.3 These tumors are generally chemo-resistant,
so the mainstays of treatment are surgical resection
and radiation therapy. The pathogenesis of ATC is
poorly understood, although key regulators of cellu-
lar metabolism such as PI3K, PTEN, RAS, and TP53
are frequently mutated. We hypothesized that
altered mitochondrial metabolism is a feature of
ATC. To test this we compared expression of two
markers of mitochondrial metabolism, monocarbo-
xylate transporter 1 (MCT1) and translocase of
the outer mitochondrial membrane member 20
(TOMM20) in ATC to that observed in noncancerous
thyroid tissue and papillary thyroid cancer (PTC).22 915
J.M. Johnson et al916MCT1 is a member of the SLC16A gene series and
is a proton-linked bidirectional transporter of mono-
carboxylic acids, specifically L-lactate, pyruvate, ace-
toacetate, propionate, and D,L-β-hydroxybutyrate.4
Expression of MCT1 at the cell surface allows for
either the import or export of monocarboxylates.5
MCT1 is the most ubiquitous of the four known
monocarboxylate transporters (MCTs) and is
expressed in red muscle fibers, myocardiocytes,
and hepatocytes.6–8 All of these cell types have high
rates of oxidative phosphorylation (OXPHOS) facili-
tated by the presence of MCT1 as the monocarbox-
ylates taken up by MCT1 are incorporated into the
mitochondrial tricarboxylic acid (TCA) cycle and the
ones MCT1 exports such as β-hydroxybutyrate and
acetoacetate are generated in the mitochondria.9,10
MCT1 expression is under the control of TP53 and
MYC.11,12 Disruption of MCT1 function can cause an
increase in intracellular lactate concentration with
downstream effects of reduced glucose transport,
reduced levels of adenosine triphosphate (ATP),
NADPH, and glutathione. As a consequence of the
reduced levels of glutathione, cells show increased
levels of hydrogen peroxide, mitochondrial damage,
and apoptosis.12 High MCT1 expression has been
found in numerous human cancer cells compared to
non-cancer cells.13–16 Expression levels of MCT1 are
prognostic in renal cell cancer and non-small cell
lung cancer.17,18
The role of MCT1 in normal thyroid metabolism
has been investigated in an in vitro model with
cultured rat FRTL-5 cells where MCT1 was found
to be expressed. Thyroid-stimulating hormone (TSH)
was noted to upregulate MCT1 expression in this
model system.19 To our knowledge there are no
studies which have examined the expression of
MCT1 in human thyroid tissue, including ATC.
Expression of the translocase of the outer mito-
chondrial membrane member 20 (TOMM20) is a
marker of mitochondrial oxidative phosphorylation
(OXPHOS) metabolism.20–22 Increased uptake of
nuclear encoded mitochondrial OXPHOS proteins
is a mechanism by which cells adapt to increased
energy demand.20 Only 13 of the OXPHOS subunit
proteins are encoded by the mitochondrial genome
and hence the majority of the subunits are encoded
in the nucleus and must be imported to the mito-
chondria through the translocase of the outer mem-
brane (TOM) complex.23 TOMM20 is the receptor
subunit of the mitochondrial import pore.24 No
publications to our knowledge have studied the
expression of TOMM20 in either normal thyroid
tissue or in thyroid cancers. TSH increases TOMM20
expression in cardiac myocytes.25 TOMM20 also has
been investigated in cancer cell metabolism and in
gastric cancer has been shown to be a negative
prognostic marker.26 In head and neck cancer, highTOMM20 expression is found in highly proliferative
(Ki-67–positive) cancer cells.21
In summary, MCT1 is a bidirectional transporter
of monocarboxylates such as lactate, pyruvate,
β-hydroxybutyrate, and acetoacetate. MCT1-
mediated uptake of monocarboxylates increases
mitochondrial metabolism as they serve as substrates
for the TCA cycle and OXPHOS. Conversely the
export of monocarboxylates generated via mitochon-
drial metabolism via MCT1 protects cells from
catastrophic oxidative stress. TOMM20 is the main
subunit of the import pore for proteins to enter the
mitochondria and it allows mitochondrial localiza-
tion of nuclear encoded OXPHOS subunits. Expres-
sion of TOMM20 correlates with mitochondrial mass
and OXPHOS function. In this study, we have
partially characterized the metabolic profile of ana-
plastic thyroid cancer by analyzing expression of
MCT1 and TOMM20 in human specimens and mouse
orthotopic xenograft tumors.MATERIAL AND METHODS
Subjects
The protocol for this study was approved by the
Institutional Review Board at Thomas Jefferson Uni-
versity. Tissue specimens of anaplastic thyroid can-
cer were obtained from 15 subjects at Thomas
Jefferson University Hospital. Patient data were
collected including age, sex, staging, tumor mor-
phology, treatment, and recurrence.
Samples and Immunohistochemistry
A total of 15 human samples of anaplastic thyroid
carcinoma were studied to evaluate markers associ-
ated with metabolism in the cancer cells of our
tumor samples. Eight noncancerous thyroid speci-
mens including five nodular goiters, three hyper-
plastic nodules, and one benign biopsy were used as
normal controls. Twelve specimens of papillary
thyroid cancer also were used for comparison. All
human cases studied were from 2010 through 2014.
For all cases, all available surgical resection or biopsy
materials were reviewed to confirm the diagnosis.
Samples consisted of a minimum of a core biopsy.
No needle aspirate specimens were considered. Nine
ATC xenografts were studied by MCT1 and TOMM20
immunohistochemistry.
Samples were stained by immunohistochemistry
for MCT1 and TOMM20. All cancer present on a slide
and its dominant staining pattern were considered
when determining the percent of immunohisto-
chemistry-positive cancer cells in a sample. Each
case was reviewed independently by two patholo-
gists who performed the evaluation blinded to
clinical outcome.
Mitochondrial metabolism as a treatment target in ATC 917An empirically derived scaling system was created
based on evident staining patterns in the samples. An
MCT1 staining score of low or high was given
ifo30% orZ30% of cells stained strongly on the
plasma membrane. TOMM20 was considered high
when at least 70% of cells demonstrated strong,
diffuse cytoplasmic staining. All other cases were
considered low.
Quantitative analysis of TOMM20 was also per-
formed employing digital pathology with Aperio soft-
ware as previously described.27 Briefly, tissue sections
were scanned on a ScanScope XT with an average
scan time of 120 seconds (compression quality 70).
Images were analyzed using the Color Deconvolution
and the Colocalization Aperio Image Analysis tool.
Areas of staining were color separated from hematox-
ylin counter-stained sections and the intensity of the
staining was measured on a continuous 0 (bright
white) to 255 (black) scale. For each case three
representative areas of the tumor were analyzed.
Human tissues for analysis were fixed in neutral
buffered formalin and then embedded in paraffin.
Sections (4 mm) were dewaxed, rehydrated through
graded ethanols, and antigen retrieval was per-
formed in 10 mmol/L citrate buffer, pH 6.0, for 10
min using a pressure cooker. The sections were
cooled, blocked with 3% hydrogen peroxide and
then for endogenous biotin using the Dako Cytoma-
tion Biotin Blocking Sytem (Dako). Sections were
next incubated with 10% goat serum for 30 minutes,
followed by primary antibodies overnight at 41C
(Santa Cruz Biotechnology, Santa Cruz, CA; MCT1
H-1, sc-365501 and TOMM20 F-10, sc-17764). Pri-
mary antibody binding was detected with a biotiny-
lated species-specific secondary antibody (Vector
Labs) followed by a streptavidin-horseradish perox-
idase conjugate (Dako). Immunoreactivity was
revealed with 3,30-diaminobenzidine (Dako). Sec-
tions were counterstained with hematoxylin.Orthotopic Xenograft Model
In addition to human samples, orthotopic xenograft
tumors of ATC were examined. Male athymic nude
mice (8–12 weeks old) were purchased from the
National Cancer Institute, maintained in a specific
pathogen-free animal facility and fed with sterilized
food and water in laminar flow cabinets. Animal
procedures and handlings were in accordance with
the protocol approved by the IACUC at University of
Texas MD Anderson Cancer Center. Male athymic
nude mice were injected with 2.5 x 105 U-HTH83
cells expressing a luciferase reporter into the right
thyroid lobe as previously described.28–30 The original
U-HTH83 cell line was established from a 66-year-old
man with a rapidly enlarging giant cell ATC.31 Animals
were killed and tumors were harvested. Sectionedmaterials were stained in an identical fashion to those
of our patient samples, as detailed above.
Statistics
The expression of MCT1 and TOMM20 in human
anaplastic thyroid specimens was compared to both
non-malignant and PTC specimens considering the
staining as a continuous variable using analysis of
variance (ANOVA) and assuming equal variance in
the data sets.RESULTS
Baseline Patient Characteristics
Our patients included 15 individuals with a diag-
nosis of ATC treated at Thomas Jefferson University
Hospital between the years of 2010 and 2014 as
shown in Table 1. The female to male ratio was 3:2
and the median age was 75.1 years (range 51–84).
The staging of these tumors was as follows: eight of
the 15 patients had confirmed nodal involvement at
the time of diagnosis, four patients did not have nodal
involvement, and in three patients the lymph nodes
were not assessed. Multiple histologic subtypes were
represented with two of 15 with giant cell features,
five with squamous differentiation, and three with
spindle cells. Seven of the 15 tumors appeared to
have arisen within the background of a papillary
carcinoma, while one appeared to have arisen in a
follicular carcinoma. Eight of the 15 patients under-
went a surgical debulking procedure with lymph
nodes addressed while the other seven patients were
diagnosed with core biopsy only before proceeding
on to radiation therapy. Two patients enrolled in
hospice after their diagnostic biopsy and another
patient declined further treatment after a total thyroi-
dectomy and lymph node dissection. Of the remain-
ing 12 patients, nine had multimodal therapy with
chemotherapy and radiation and three underwent
radiation alone. Chemotherapeutic regimens were
highly varied and included docetaxel, paclitaxel,
cisplatin, carboplatin, doxorubicin, sorafenib, and an
ongoing clinical trial with pazopanib (Radiation Ther-
apy Oncology Group [RTOG] 0912).
Survival Data
Of the 15 patients presented here, two were alive
at the time of data analysis. Their survival time was
calculated as of our defined cut-off date. When all
patients, including those alive at the time of our data
analysis, are included the median survival time was
188 days with a range from 15–447þ days. When
only those who have succumbed to their disease
are analyzed (13 of the 15 cases) the average survival
is 161 days. Thus these cases appear to be
Table 1. Patient Characteristics, MCT1, and TOMM20 Expression by Immunohistochemistry.
Sample
TOMM20
Cancer
MCT1
Cancer Sex
Age
(yr) T N M Surgery Treatment
Survival
(days)
1 High High M 54 4b 1 0 Total, RND Chemo/XRT 447*
2 High High M 83 4b 1b 0 Total, BLND Chemo/XRT 208
3 High High F 83 4b 0 0 Bx Chemo/XRT 304
4 High High F 73 4b 1b 0 L lobe, BLND Chemo/XRT 205
5 High High F 84 4a 0 0 Bx N 19
6 High High F 82 4b X 1 Bx N 15
7 Low High F 84 4b X 1 Bx XRT 46
8 High Low M 79 4b 1b 1 Total, PND, LND Chemo/XRT 149
9 High High F 83 4b X 1 Bx XRT 163
10 High Low F 70 4b 1b 1 Total, BLND Chemo/XRT 215
11 High High F 75 4b 1a 0 Total, BLND Chemo/XRT 243
12 Low High M 61 4a 1b 0 Total, LND N 115
13 High High F 79 4b 1b 0 Bx Chemo/XRT 224
14 Low High M 84 4a 0 0 Bx XRT 189
15 High High M 51 4a 0 0 Total, PND Chemo/XRT 280*
n Alive as of September 1, 2015.
NOTE: T, N, M indicate tumor, node, and metastasis stage; Surgery: Total ¼ total thyroidectomy; RND ¼ right neck dissection;
LND ¼ left neck dissection; BLND ¼ bilateral neck dissection; PND ¼ paratracheal neck dissection; Bx ¼ biopsy.
J.M. Johnson et al918representative of anaplastic thyroid cancer with
respect to survival statistics.
High Expression of MCT1 Is Seen in ATC
Specimens Relative to Noncancerous and PTC
Specimens
In the panel of 15 ATC specimens, 13 samples
showed high expression of MCT1 (Table 1,
Figure 1C). In contrast, PTC and noncancerous
thyroid tissue failed to show this high level of
expression (Figures 1A, B). In summary, 13 of 15
ATC had high expression of MCT1, none of eight
normal samples had high expression (Po.0001)
(Figure 1E). In the 12 samples of PTC, 10 had low
levels of staining for MCT1 (Po.001) (Figure 1E).
Of the two that stained for MCT1, one sample
represented the contralateral lobe of a patient who
had presented with anaplastic thyroid cancer (speci-
men no. 15 in Table 1). Thus, MCT1 protein
expression is a distinguishing feature of anaplastic
thyroid cancer compared to PTC and noncancerous
thyroid samples. When the orthotopic xenograft
mouse models also were assessed by immuno-
histochemistry, all samples tested demonstrated
high expression of MCT1 in the tumor cells,
reiterating this phenotype (Figure 1E, Table 2).
Surrounding noncancerous mouse tissue did not
stain for MCT1.
High TOMM20 Is Observed in ATC Specimens
Relative to Noncancerous Thyroid Tissue
The functional mitochondrial mass of anaplastic
thyroid cancer cells was assessed via TOMM20expression. High expression of TOMM20, defined
as470% of the cells staining, was seen in 12 of the
15 cases of ATC (Table 1, Figure 2C). Low expres-
sion of TOMM20 was seen in all eight samples of
noncancerous thyroid tissue (Figure 2A). Similar to
the ATC specimens, PTC demonstrated high stain-
ing in contrast to the noncancerous thyroid tissue
(Figure 2B). When TOMM20 expression by immu-
nohistochemistry was assessed in the orthotopic
xenograft model, the cancer cells in all nine sam-
ples stained in a pattern similar to the human ATC
specimens (high staining of TOMM20 in tumor
tissue and none in surrounding mouse tissue) again
reiterating this metabolic signature (Figure 2E,
Table 2).
We further investigated the staining of these
samples using digital quantification. Comparisons
were made between the carcinoma cells from
patients with ATC and the noncancerous thyroid
tissue in the same samples with the Aperio digital
quantification system. This system is able to com-
pare the overall intensity of stain per object (tumor
cell) in a selected area. With a previously validated
algorithm for TOMM20 analysis we were able to
establish an average stain intensity of 164.06 in our
anaplastic specimens versus 177.0 in the noncan-
cerous controls. The higher numeric value in this
system correlates to a lower stain intensity. Thus,
there is significantly more TOMM20 staining in
ATC compared to noncancerous thyrocytes
(Po.05). To account for the higher numeric value
correlating with a lower stain intensity, these were
graphically represented as mathematical inverses
(Figure 2D).
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Figure 1. Representative photomicrographs showing MCT1 staining by immunohistochemistry in patient samples
representing: (A) noncancerous, normal thyroid tissue, (B) papillary thyroid carcinoma (PTC) and (C) human anaplastic
thyroid carcinoma (ATC). (D) Quantiﬁcation of the average number of cells expressing MCT1 by immunohistochemistry
seen in normal human thyroid tissue as compared to PTC and ATC; error bars represent the standard error of the mean.
(E) MCT1 staining of orthotopic xenograft model of ATC. All images are at 40x magniﬁcation.
Mitochondrial metabolism as a treatment target in ATC 919To determine if this elevation of mitochondrial
mass was also present in other thyroid malignancies,
we compared ATC to PTC. Twelve PTC cases were
compared using the same TOMM20 Aperio algo-
rithm to the ATC cases as described above. There
was no statistically significant difference in average
intensity between PTC (intensity of 160.2) com-
pared to ATC (intensity 164.06) (P4.05)
(Figure 2D). However, as previously described,
TOMM20 intensity is greater in ATC than in the
noncancerous samples (Po.001).Table 2. MCT1 and TOMM20 Expression by Immu
Specimen No.
TOMM20
Cancer
TOM
Non-c
1 High Lo
2 High Lo
3 High Lo
4 High Lo
5 High Lo
6 High Lo
7 High Lo
8 High Lo
9 High LoDISCUSSION
We demonstrate here that in human anaplastic
thyroid cancer there is high expression of MCT1 and
TOMM20 compared to noncancerous thyroid tissue.
The high expression levels of these two markers of
monocarboxylate transport and mitochondrial
metabolism support our hypothesis that deranged
cellular metabolism is a feature of ATC.
High MCT1 expression is a feature of ATC
compared to normal thyroid tissue and PTC. Wenohistochemistry in Mouse Xenograft Models
M20
ancer
MCT1
Cancer
MCT1
Non-cancer
w High Low
w High Low
w High Low
w High Low
w High Low
w High Low
w High Low
w High Low
w High Low
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Figure 2. Representative photomicrographs showing TOMM20 staining by immunohistochemistry in patient samples
representing: (A) noncancerous, normal thyroid tissue, (B) papillary thyroid carcinoma (PTC), and (C) human anaplastic
thyroid carcinoma (ATC). All images are at 40x magniﬁcation. (D) Average stain intensity of TOMM20 by digital
quantiﬁcation of immunohistochemistry in normal human thyroid tissue as compared to PTC and ATC. The Y axis
represents the inverse of the numeric output of the Aperio analysis system. Error bars represent the standard error of the
mean. (E) TOMM20 staining of orthotopic xenograft model of ATC. Image at 20x magniﬁcation.
J.M. Johnson et al920hypothesize that this is directly related to the high
rate of OXPHOS being conducted in these cancerous
cells, similar to other metabolically active cell types
already known to express MCT1. MCT1’s presence
would enable import of pyruvate and lactate to fuel
mitochondrial respiration,32–35 giving them a signifi-
cant growth advantage.
While MCT1 is highly expressed in the ATC
samples, the PTC samples rarely showed high
expression. This contrast is reiterated in the clinical
phenotypes of the two cancers. ATC shows high
growth kinetics and a short overall survival while
PTC is more indolent with a much better prognosis.
The 5-year overall survival for ATC is 7% while for
PTC it is over 90%. Well-differentiated thyroid carci-
noma is thought to be the precursor lesion for the
development of ATC. In future in vitro experiments
it will be important to determine if high MCT1 is
necessary or sufficient to induce the transformation
of PTC into ATC.
Also of interest is the identification of the main
monocarboxylates being transported by MCT1 in
ATC and whether MCT1 is involved predominantly
in their import or export in this disease. High uptake
of 13C- pyruvate in tumors has been noted in these
ATC xenografts.28,36 Uptake of 13C-pyruvate in these
xenografts is most likely mediated by MCT1 sincethis is the main importer of pyruvate into cells, but
this will need to be confirmed experimentally.
High TOMM20 expression also is found in human
ATC in contrast to low expression in normal thyro-
cytes. Like the expression of MCT1, TOMM20
expression is associated with high OXPHOS as it is
a key component of the mitochondrial outer mem-
brane (MOM) protein import system for nuclear
encoded subunits of OXPHOS,37 specifically, the
import of precursor proteins containing mitochon-
drial targeting sequences.22 It has been shown that
TOMM20 RNA interference inhibits the MOM target-
ing and mitochondrial localization of nuclear
encoded respiratory chain complexes, whereas
TOMM20 overexpression has the opposite effects.22
Future studies will need to discover the regulators of
TOMM20 expression in ATC.
The involvement of mitochondrial metabolism
shown in this paper is also supported by the genetic
signature of ATC. Frequently found mutations in ATC
include TP53, H-, N-, or KRAS, BRAF (V600E
mutation), PIK3CA, PIK3CB, and PTEN.38–40 Hence,
the most frequent genetic alterations in ATC are in
the RAS/RAF/ERK and the PI3K/PTEN pathway. Both
of these signal transduction pathways are known
metabolic modulators. RAS drives mitochondrial
metabolism. Activation of RAS signaling increases
Mitochondrial metabolism as a treatment target in ATC 921the mitochondrial TCA cycle.41 This classic member
of the MAPK pathway also plays a role in the PI3K/
AKT pathway by binding directly to PI3K at the p110
subunit. Loss of wild-type TP53 also increases mito-
chondrial metabolism42 and in conjunction with
activation of RAS increases OXPHOS.43 TP53 muta-
tions also induce expression of MCT1.11 In summary,
the current literature on genetic alterations in ATC
both supports the involvement of mitochondrial
metabolism and specifically the involvement of
MCT1. In the future it will be of interest to determine
experimentally if they are the drivers of the ATC
metabolic phenotype discovered in the current study.
Despite our growing knowledge of the genetic
alterations in ATC, it has been difficult to target these
mutations to improve outcomes in this disease. By
studying the metabolic characteristics of ATC and
finding differences with noncancerous tissues and
precursor lesions such as PTC we can develop and
study drugs that preferentially target the cancer cells
and spare normal counterparts. It already has been
shown that inhibitors of glycolysis such as 2-
deoxyglucose preferentially target ATC in animal
models.36 Currently, MCT1 inhibitors are being
tested for the treatment of human malignancies
and may be valuable for the treatment of ATC.44
Also, mitochondrial inhibitors such as metformin
may hold promise to treat ATC.45 The two markers
of mitochondrial metabolism assessed here,
TOMM20 and MCT1, are highly expressed in ATC
compared to normal thyrocytes and future work will
determine if these are viable therapeutic targets.Acknowledgments
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